BCAB
BCAB
NASDAQ · Biotechnology

Bioatla Inc

$1.48
-0.04 (-2.63%)
Analyst Consensus
Strong Buy
7
Analysts
Moderate
Coverage
Buy 6 86%
Hold 1 14%
Sell 0 0%
Price Target
Analyst Price Target +535.1% upside
Low Target $5.45
Average Target $9.40
High Target $11.97
Current Price $1.48
Current
$1.48
Target
$9.40
$5.45 $9.40 avg $11.97
Scenario Analysis
Bear Case
$5.45
268.2%
Low target
Base Case
$9.40
+535.1%
Avg target
Bull Case
$11.97
+708.8%
High target
Risk/Reward
2.6x
Favorable
Price in Context
52-Week High
$71.50
-97.9% from high
52-Week Low
$1.07
+38.3% from low
Target vs 52W High
$9.40
-86.9% vs high
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Strong Buy 39 82% $257.58 -3.3%
AMGN
Amgen Inc
Hold 43 47% $190.87 -54.4%
GILD
Gilead Sciences Inc
Strong Buy 37 81% $362.68 +138.3%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 36 81% $438.34 -16.9%
REGN
Regeneron Pharmaceuticals
Buy 38 68% $76.80 -89.8%
MRNA
Moderna Inc
Hold 30 37% $149.45 -24.2%
NTRA
Natera Inc
Strong Buy 30 87% $142.91 -65.3%
RVMD
Revolution Medicines Inc
Strong Buy 28 93% $114.11 -43.4%